72 related articles for article (PubMed ID: 24065472)
1. Oxidative and antioxidative status after anthracyclinebased chemotherapy in breast cancer patients.
Alacacioglu A; Kebapcilar L; Onder Pamuk B; Sop G; Kucukiravul C; Bozkaya G; Yuksel A; Alacacioglu I; Sari I
J BUON; 2013; 18(3):614-8. PubMed ID: 24065472
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
3. Taxane-based adjuvant chemotherapy reduces endothelin-1 and symmetric dimethylarginine levels in patients with breast cancer.
Alacacioglu A; Kebapcilar L; Sari I; Gokgoz Z; Tarhan O; Somali I; Yuksel A; Bozkaya G; Sop G
J BUON; 2010; 15(3):572-6. PubMed ID: 20941830
[TBL] [Abstract][Full Text] [Related]
4. Lipid peroxidation and antioxidant status in patients with breast cancer.
Rajneesh CP; Manimaran A; Sasikala KR; Adaikappan P
Singapore Med J; 2008 Aug; 49(8):640-3. PubMed ID: 18756349
[TBL] [Abstract][Full Text] [Related]
5. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
7. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer: interaction between oxidant-antioxidant dynamics and inflammation in Indian females.
Goswami B; Rajappa M; Gupta N; Mahto M; Hadke NS; Mishra TK
Cancer Biomark; 2010; 6(2):95-103. PubMed ID: 20571235
[TBL] [Abstract][Full Text] [Related]
9. Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients.
Wachter DL; Fasching PA; Haeberle L; Schulz-Wendtland R; Dimmler A; Koscheck T; Renner SP; Lux MP; Beckmann MW; Hartmann A; Rauh C; Schrauder MG
Arch Gynecol Obstet; 2013 Feb; 287(2):337-44. PubMed ID: 22955249
[TBL] [Abstract][Full Text] [Related]
10. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of neutropenia on day one of anthracycline-based neoadjuvant chemotherapy in operable breast cancer.
Ishitobi M; Komoike Y; Motomura K; Koyama H; Inaji H
Oncology; 2010; 78(3-4):213-9. PubMed ID: 20424493
[TBL] [Abstract][Full Text] [Related]
12. Effect of vitamins C and E on antioxidant status of breast-cancer patients undergoing chemotherapy.
Suhail N; Bilal N; Khan HY; Hasan S; Sharma S; Khan F; Mansoor T; Banu N
J Clin Pharm Ther; 2012 Feb; 37(1):22-6. PubMed ID: 21204889
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy.
Panis C; Herrera AC; Victorino VJ; Campos FC; Freitas LF; De Rossi T; Colado Simão AN; Cecchini AL; Cecchini R
Breast Cancer Res Treat; 2012 May; 133(1):89-97. PubMed ID: 21811816
[TBL] [Abstract][Full Text] [Related]
14. Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy.
Bonneterre J; Révillion F; Desauw C; Blot E; Kramar A; Fournier C; Hornez L; Peyrat JP
Oncol Rep; 2013 Jan; 29(1):355-61. PubMed ID: 23117275
[TBL] [Abstract][Full Text] [Related]
15. Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients.
Rzymowska J
Pathobiology; 1999; 67(3):129-32. PubMed ID: 10394133
[TBL] [Abstract][Full Text] [Related]
16. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
[TBL] [Abstract][Full Text] [Related]
17. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
Ramaswamy B; Povoski SP; Rhoades C; Allen J; Hauger M; Young D; Burak W; Farrar W; Yee L; Kendra K; Somasundaram S; Orlowski RZ; Shapiro CL
Breast Cancer Res Treat; 2005 Sep; 93(1):67-74. PubMed ID: 16184461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
